Increased complement activation 3 to 6 h after trauma is a predictor of prolonged mechanical ventilation and multiple organ dysfunction syndrome: a prospective observational study

Ingrid Nygren Rognes1,2, Søren Erik Pischke3,4, William Ottestad2,3, Jo Røislien1,5, Jens Petter Berg2, Christina Johnson4, Torsten Eken2,3 and Tom Eirik Mollnes4,6,7*

Abstract

Background: Complement activation is a central mechanism in systemic inflammation and remote organ dysfunction following major trauma. Data on temporal changes of complement activation early after injury is largely missing. We aimed to describe in detail the kinetics of complement activation in individual trauma patients from admission to 10 days after injury, and the association with trauma characteristics and outcome.

Methods: In a prospective cohort of 136 trauma patients, plasma samples obtained with high time resolution (admission, 2, 4, 6, 8 h, and thereafter daily) were assessed for terminal complement complex (TCC). We studied individual TCC concentration curves and calculated a summary measure to obtain the accumulated TCC response 3 to 6 h after injury (TCC-AUC3-6). Correlation analyses and multivariable linear regression analyses were used to explore associations between individual patients’ admission TCC, TCC-AUC3-6, daily TCC during the intensive care unit stay, trauma characteristics, and predefined outcome measures.

Results: TCC concentration curves showed great variability in temporal shapes between individuals. However, the highest values were generally seen within the first 6 h after injury, before they subsided and remained elevated throughout the intensive care unit stay. Both admission TCC and TCC-AUC3-6 correlated positively with New Injury Severity Score (Spearman’s rho, p-value 0.31, 0.0003 and 0.21, 0.02) and negatively with admission Base Excess (−0.21, 0.02 and −0.30, 0.001). Multivariable analyses confirmed that deranged physiology was an important predictor of complement activation. For patients without major head injury, admission TCC and TCC-AUC3-6 were negatively associated with ventilator-free days. TCC-AUC3-6 outperformed admission TCC as a predictor of Sequential Organ Failure Assessment score at day 0 and 4.

Conclusions: Complement activation 3 to 6 h after injury was a better predictor of prolonged mechanical ventilation and multiple organ dysfunction syndrome than admission TCC. Our data suggest that the greatest surge of
complement activation is found within the first 6 h after injury, and we argue that this time period should be in focus in the design of future experimental studies and clinical trials using complement inhibitors.

**Keywords:** Wounds and injuries, Humans, Complement activation, Complement membrane attack complex, Systemic inflammatory response syndrome, Multiple organ failure, Mortality

**Background**

Trauma is one of the main causes of premature death world-wide (GBD 2019 Diseases and Injuries Collaborators 2020). The innate immune response initiated by trauma, a response evolved to restore homeostasis after mild and moderate injuries, can be exaggerated and sustained in patients with severe trauma. Severely injured patients who survive the initial insult may suffer from detrimental systemic inflammation and subsequent remote organ dysfunction. Tissue injury leads to immediate release of endogenous danger signals that trigger a cascade of innate immune pathways, potentially leading to a systemic inflammatory response and multiple organ dysfunction syndrome (MODS) (Lord et al. 2014). MODS can be evident as early as at the day of admission in severely injured patients, and patients presenting with MODS have a prolonged intensive care unit (ICU) stay and increased mortality (Cole et al. 2020). The extent and immediacy of the immunological response is evidenced by genome-wide analyses of human blood leukocytes, showing an alteration in immune cell genes already within 2 h after injury (Cabrera et al. 2017).

The complement system is a crucial sensor of cellular stress and damage (Matzinger 2002; Hajishengallis et al. 2017; Huber-Lang et al. 2018), and its role in trauma has been investigated in human observational studies since the 1980s (Fosse et al. 1987, 1998; Zilow et al. 1992; Donnelly et al. 1994; Meade et al. 1994; Roumen et al. 1995; Hecke et al. 1997; Ganter et al. 2007; Amara et al. 2009; Burk et al. 2012; Li et al. 2019; Huber-Lang et al. 2013; Chakraborty et al. 2018). Excessive complement activation has been reported within minutes after major trauma (Burk et al. 2012). A rapid consumption of complement factors and severe dysfunction of regulatory mechanisms can be seen in some severely injured patients, a state termed complementopathy (Amara et al. 2009; Burk et al. 2012).

Activation of complement occurs through three pathways: the classical, the lectin, and the alternative pathway, however, there is debate regarding which pathway is the most important in trauma (Ganter et al. 2007; Li et al. 2019). All three pathways converge at the central complement components (C) C3 and C5, with subsequent formation of the anaphylatoxins C3a and C5a and the terminal C5b-9 complement complex (TCC). TCC exists in two forms. The membrane-inserted form, named the membrane attack complex (MAC), can lyse bacteria and cells, but also activate the host’s own cells in sub-lytic doses (Morgan 2015), triggering further inflammation. The soluble form of TCC found in plasma (sC5b-9) is regarded biologically inert, but is the most robust activation product to evaluate systemic complement activation (Bergseth et al. 2013). It has an in vivo half-life of one hour, is relatively stable in vitro, and reflects the end stage of complement activation (Harboe et al. 2011).

Excessive complement activation after trauma has been associated with development of sepsis (Schoffel et al. 1991), acute respiratory distress syndrome (Zilow et al. 1992; Donnelly et al. 1994; Meade et al. 1994), systemic inflammation (Fosse et al. 1998) and MODS (Roumen et al. 1995; Ganter et al. 2007; Nuytinck et al. 1986), and is moreover associated with increased mortality (Roumen et al. 1995; Hecke et al. 1997; Ganter et al. 2007), increasing Injury Severity Score (ISS) and increasing physiological derangement (decreasing Base Excess, BE) (Fosse et al. 1998; Ganter et al. 2007; Sharma et al. 2004). Complement activity during the ICU stay has also been studied (Risberg et al. 1986; Zilow et al. 1992; Donnelly et al. 1994; Meade et al. 1994; Hecke et al. 1997; Fosse et al. 1998; Roumen et al. 1995; Burk et al. 2012; Li et al. 2019). However, most of these studies have only described and tested measurements of complement activation on group level at individual standardized time points, despite having a repeated-measures design. This approach poses a range of statistical problems (Matthews et al. 1990), and any information on individual concentration kinetics is lost. Further, the pathology after trauma is complex and heterogeneous with myriads of molecules released, and measurements at single time points are insufficient to describe relationships between time-varying molecular responses in full. Summary measures generated from repeated samples, e.g. area under individual concentration curves, have been proposed as useful alternatives in repeated measures analyses (Matthews et al. 1990).

There is an increasing interest in complement inhibition as a potential therapeutic strategy for trauma-induced systemic inflammation and MODS, but so far only a few experimental studies have been performed (Huber-Lang et al. 2018; Ricklin et al. 2018; Ricklin and Lambris 2013; Karasu et al. 2019). More knowledge on complement kinetics in human trauma is necessary to
improve pathophysiological understanding, elucidate the clinical effects of complement activation and theoretically explore the potential benefit of complement inhibition, before interventional studies with complement inhibitors can be initiated (Karasu et al. 2019; Groeneveld et al. 2011).

The aim of this study was to investigate temporal changes of the complement activation end product TCC in high time-resolution samples from trauma patients in the first critical hours, followed by daily samples up to 10 days following injury, in order to describe its concentration kinetics and the association with anatomical injury, physiological derangement and outcome.

Methods
Study design and approval
This prospective observational study investigated concentration kinetics of the complement activation product TCC in serially collected plasma samples from 136 trauma patients. The study is part of a greater effort to describe the innate immune response following trauma, design and methods have been described in detail previously (Ottestad et al. 2019). Reference TCC values were obtained from 20 healthy volunteers. All parts of the study were approved by the Regional committee for medical and health research ethics (2010/2014 REK Sør-Øst D), in accordance with the Declaration of Helsinki. We adhered to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for cohort studies (von Elm et al. 2007).

Setting and participants
Patients were recruited by convenience at Oslo University Hospital (OUH) Ullevål, a Norwegian Level 1 trauma centre, from January 2011 through January 2014. All patients ≥18 years old who met criteria for trauma team activation were eligible for inclusion. Pregnant women and patients with burn injuries were not included. Patients were enrolled on arrival and followed through their ICU stay, limited to 10 days or death. Survival status at 30 days after injury was verified from the Norwegian Population Registry.

Sample collection
Blood was drawn in K$_2$EDTA-coated tubes after a discard tube, immediately after admission, 2, 4, 6 and 8 h thereafter, and every morning in the ICU for up to 10 days. Sampling through an arterial cannula was preferred in order to obtain blood that was not draining from any particular injured body part. All samples were handled as recommended for analyses of complement activation products (Mollnes et al. 1988). The EDTA tubes were put directly in ice slush after 8–10 inversions and centrifuged within 15 min at 2500 g for 15 min at 4 °C. The supernatant was immediately transferred to sterile polypropylene tubes and stored at −80 °C. Peripheral venous samples from healthy volunteers were handled by the same protocol.

Laboratory analyses
Complement activation was assessed by quantifying plasma TCC (sC5b-9) using an enzyme-linked immunosorbent assay (ELISA) as described originally (Mollnes et al. 1985) and later modified (Bergseth et al. 2013). The analyses were conducted blinded to the clinicians and the clinical data. In brief, TCC formation was quantified by use of the monoclonal antibody aE11 reacting with a neoepitope of C9 exposed when incorporated into fluid-phase sC5b-9 complex. Biotinylated anti-C6 mAb (clone 9C4) was used as detection antibody. Optimal sample dilution was determined to be 1:5. Values are given in arbitrary units (AU)/mL referred to a standard curve of zymosan activated human serum defined to contain 1000 AU/mL. The standard curve and internal controls were based on the International Complement Standard #2 (Bergseth et al. 2013), made in our laboratory and stored in a biobank in Heidelberg, available to all complement laboratories worldwide. Intra and inter-assay coefficients of variation were 5% and 10%, respectively. In the present study the whole population was analysed in one batch, except for 12 patient samples analysed initially as a pilot.

In contrast to many other complement components, we have found that TCC does not change as function of sex and age. In the method paper (Bergseth et al. 2013) we investigated 10 males and 10 females from each of the age decades 20–70 (healthy registered blood donors) and found exactly the same reference range in all subpopulations, so these data could be pooled for a general normal reference range (Bergseth et al. 2013). The sample could be thawed and frozen 10 times without any change in the value (Bergseth et al. 2013). TCC is a particularly stable activation product, which can be stored for up to 10 years at −70 °C. We collected a pool of healthy blood donors in 1985, thawed them and compared them in the same assay set up with a fresh pool of healthy blood donors, and the values were identical (unpublished observations). Furthermore, we have non-published observations from patients undergoing cardiopulmonary bypass with a substantial increase in TCC. Venous and arterial samples showed exactly the same values. It is reasonable to assume that this applies also for trauma patients despite being a different
Clinical data and routine laboratory analyses
Clinical data were collected from the Oslo University Hospital Trauma Registry, ICU charts and routine blood samples. All outcome measures and predictor variables were predefined (Osler et al. 1997; Balogh et al. 2000; Ouellet et al. 2012).

Primary outcome was ventilator-free days (VFD), defined as days alive and off ventilator during the first 30 days after trauma (Schoenfeld et al. 2002; Yehya et al. 2019). Patients transferred to another hospital while still intubated were regarded as ventilator treated through the rest of the 30-day period. Secondary outcome measure was daily Sequential Organ Failure Assessment (SOFA) score (Vincent et al. 1998) (Methods in Additional file 1). New Injury Severity Score (NISS) was chosen as a measure for overall injury severity (Osler et al. 1997; Balogh et al. 2000), and admission BE, assessed by arterial blood gas analysis within minutes of arrival in the trauma room (Cobas b 221 blood gas system, Roche Diagnostics Norway AS), as the primary measure for physiological derangement (Ouellet et al. 2012). Remaining predictor variables were admission TCC concentration and area under the individual TCC concentration curves during the time period from 3 to 6 h after injury (TCC-AUC_{3–6}) (Ottestad et al. 2019), sex, age, and mechanism of injury (blunt or penetrating).

Patients with major head injury receive organ support due to the head injury per se, thereby affecting both VFD and SOFA score. Patients with and without an Abbreviated Injury Scale (AIS) severity code ≥ 3 in ISS region Head or neck were therefore analysed as separate populations.

Statistical analyses
All sampling times were converted to elapsed time from injury. Concentrations of TCC were linearly interpolated to enable comparison of data at specific time points after injury across our asynchronously sampled data (Ottestad et al. 2019). The linearly interpolated dataset was also used to calculate a summary measure, area under the individual TCC curve 3–6 h after injury, and to assess Daily TCC. Details are given in Methods in Additional file 1.

Correlation between continuous variables was assessed by Spearman’s rank correlation coefficient (ρ). Group comparisons were performed by Fisher’s exact test for categorical data and Wilcoxon rank-sum test (Mann-Whitney) for continuous data.

Relationships between predictor and response variables were examined in multivariable linear regression models with backward elimination. The optimal model was selected using the Bayesian information criterion (BIC) (Neath and Cavanaugh 2012). Assessment of importance of the individual predictor variables was performed as variance-based sensitivity analysis (Saltelli 2002). Importance indices were constructed from observed combinations of factor values, since predictor variables were generally correlated. There were indications of non-linear associations between independent and dependent variables, and generalised additive models (GAMs) (Wood 2017), a generalisation of traditional linear regression models, were also explored, without significant impact on results.

A two-tailed p value ≤ 0.05 was chosen to represent statistical significance. Data analyses were undertaken using JMP 13.2.0 (SAS Institute, Cary, NC). GAM was performed using the function gam in the mgcv package version 1.8–17 in R 3.3.3 through the GAMs V1.0 JMP add-in.

Extreme outlier TCC values
Three patients had extreme outlier TCC values, Fig. S1 in Additional file 2. One patient with minor injuries, NISS 5 and BE -2.6, had admission TCC concentration 14.1 AU/mL and a similarly elevated level two hours later. It was suspected that reliable values were not possible to obtain, conceivably due to heterophilic antibodies in the patient’s plasma (Bolstad et al. 2013). Two other patients had TCC levels above upper detection limit for the assay that could not be diluted to measurable levels, therefore invalidating calculation of area under the TCC concentration curves. The three patients are included in descriptive statistics but excluded from figures, comparisons, correlation and regression analyses.

Results
Study population
Out of 145 originally enrolled patients, 136 constituted the study population (Fig. S1 in Additional file 2), identical to the one reported in our previous paper (Ottestad et al. 2019). Demographics and clinical characteristics for the total population are given in Table 1, and the corresponding data for differences between patients with or without major head trauma in Table S1 in Additional file 3. Twenty patients died, 16 during the first 48 h, mainly due to major brain injury (n = 9) and excessive haemorrhage (n = 5) (Fig. S2 in Additional file 4).

Complement concentration kinetics after trauma
TCC concentration curves were heterogeneous among the individual trauma patients. Complement was already activated on admission and TCC concentrations were generally highest within the first 6 h after...
injury (Figs. 1 and 2). Admission TCC in the study population \((n = 136)\) ranged from 0.08 to 14.1 AU/mL with median (quartiles) concentration 0.87 AU/mL (0.60–1.57). Admission TCC was significantly higher among patients (median [quartiles; range] 0.85 AU/mL [0.59–1.50; 0.08–12.14], \(n = 133\), the three extreme outliers removed) than among the healthy volunteers (0.42 AU/mL [0.27–0.79; 0.08–1.52], \(n = 20\)) \((p = 0.0002)\) (Fig. 3a). Admission TCC was higher in blunt (0.89

| Table 1 Characteristics of study population and controls |
|--------------------------------------------------------|
| Characteristics                                      | Trauma patients \((n = 136)^a\) | Healthy controls \((n = 20)\) |
| Demographics                                          |                                |                                |
| Sex (male : female)                                   | 101 : 35                       | 11 : 9                         |
| Age (years)                                           | 40 (18–94); \(n = 135\)       | 39 (22–58)                     |
| Preinjury ASA PS (ASA I : II : III)                   | 85 : 37 : 14                  |                                |
| Injuries                                              |                                |                                |
| Mechanism of injury (blunt : penetrating)             | 118 : 18                       |                                |
| NISS                                                   | 27 (1–75)                      |                                |
| ISS                                                    | 19 (1–75)                      |                                |
| Serious injury (NISS ≥ 16; ISS ≥ 16)                  | 92 : 80                        |                                |
| Critical injury (NISS ≥ 25; ISS ≥ 25)                 | 75 : 57                        |                                |
| Major head injury\(^b\) (yes : no)                    | 59 : 77                        |                                |
| Admission BE (mmol/L)                                 | –3.1 (–26.0–3.4); \(n = 127\) |                                |
| Admission BE ≤ –6 mmol/L (\(n\))                     | 32                             |                                |
| TCC analyses                                          |                                |                                |
| Admission TCC (AU/mL)                                 | 0.87 (0.08–14.1); \(n = 136\) | 0.42 (0.08–1.52)               |
| TCC-AUC \(_{–6}^{3}\) (AU/mL x h)                    | 2.49 (0.25–52.6); \(n = 120\) |                                |
| Time from injury to first sample (hours : minutes)    | 1:15 (0.20–5:40)              |                                |
| Samples analysed per patient                          | 6 (1–35)                      |                                |
| Mean interpolated TCC (AU/mL)                         |                                |                                |
| Day 0                                                  | 0.88 (0.17–15.1); \(n = 136\) |                                |
| Day 4                                                  | 1.91 (0.08–12.7); \(n = 39\)  |                                |
| Day 7                                                  | 2.24 (0.72–15.2); \(n = 28\)  |                                |
| Day 9                                                  | 2.39 (0.53–21.4); \(n = 23\)  |                                |
| Hospital treatment                                    |                                |                                |
| Transfused before ICU (yes : no : unknown)            | 30 : 105 : 1                   |                                |
| Transfusions before ICU (PRBC units)                  | 9 (1–61); \(n = 30\)          |                                |
| Hospital length of stay (days)                        | 6 (1–52)                      |                                |
| ICU length of stay                                    | 3 (1–52); \(n = 131\)         |                                |
| SOFA score                                            |                                |                                |
| Day 0                                                  | 6 (0–16); \(n = 133\)         |                                |
| Day 4                                                  | 9 (1–15); \(n = 39\)          |                                |
| Day 7                                                  | 9 (1–14); \(n = 26\)          |                                |
| Day 9                                                  | 9 (0–15); \(n = 20\)          |                                |
| Ventilator treatment (yes : no)                       | 67 : 69                       |                                |
| Survival                                               |                                |                                |
| Dead at 30 days (yes : no)                            | 20 : 116                      |                                |
| Time to death (days)                                  | 1 (0–23); \(n = 20\)         |                                |
| Predefined outcome variable                           |                                |                                |
| Ventilator–free days                                  | 29 (0–30)                     |                                |

Values are given as median and range unless otherwise stated

\(^a\) \(n\) is given where group size is < 136

\(^b\) Major head injury was defined as maximum Abbreviated Injury Scale (AIS) severity code ≥ 3 in ISS region Head or neck

ASA PS American Society of Anesthesiologists Physical Status Classification System, NISS New Injury Severity Score, ISS Injury Severity Score, BE Base Excess, AU Arbitrary units, ICU Intensive Care Unit, PRBC Packed Red Blood Cells, SOFA score Sequential Organ Failure Assessment score
AU/mL [0.62–1.59; 0.08–12.14], n = 116) than penetrating (0.63 AU/mL [0.44–0.99; 0.08–4.01], n = 17) injury (p = 0.01, Fig. 3b), increased with both increasing NISS (ρ = 0.31, p = 0.0003) and decreasing BE (ρ = -0.21, p = 0.02) (Table S2 in Additional file 5), and was not statistically different between males and females (median 0.76 AU/mL vs. 0.93 AU/mL, respectively, p = 0.52).

Individual TCC concentration curves varied substantially from admission through day 10 after trauma (Fig. 2). We first investigated individual responses during the initial 24 h, for which a pattern emerged when TCC concentration curves were stratified by NISS and admission BE (Fig. 1). The impact of complement activation on the immune system was presumed to be a function not only of admission concentration but also concentration over time. In order to study this, we calculated area under the individual TCC concentration curve from 3 to 6 h after injury (TCC-AUC 3–6) (Methods in Additional file 1 and illustrated as grey columns in Fig. 1). TCC-AUC 3–6 was median (quartiles; range) 2.49 AU/mL x h (1.84–4.23; 0.25–52.6) (Table 1). TCC-AUC 3–6 increased with increasing admission TCC (ρ = 0.72, p < 0.0001) (Fig. 3c) and NISS (ρ = 0.21, p = 0.02), and with decreasing BE (ρ = -0.30, p = 0.001) (Table S2 in Additional file 5), but was not affected by injury mechanism (blunt median 2.47 AU/mL vs. penetrating 2.78 AU/mL, p = 0.87) or sex (males median 2.41 AU/mL vs. females 3.20 AU/mL, p = 0.35).

**Complement activation and outcome**

For our primary outcome measure VFD, observations clustered at the extremes of the scale (0 and 30 days, Fig. 4). In non-parametric bivariable analyses for the total population (Table S2 in Additional file 5) both admission TCC and TCC-AUC 3–6 were correlated with VFD. Patients with low SOFA score (≤ 6) at the day of admission appeared to have lower admission TCC concentrations than patients with high SOFA score (> 6), Fig. 5. At day 9 however, there was apparently no difference between TCC concentration curves in patients with low and high SOFA score. In regression analyses, this apparent trend was confirmed; admission TCC, TCC-AUC 3–6, and same-day TCC measurements were correlated with the secondary outcome SOFA score on day 0 and 4 after injury, but not on day 7 and 9 (Fig. S3 in Additional file 6). Both admission TCC and TCC-AUC 3–6 were higher in patients who died (median 1.52 AU/mL vs. 0.81 AU/
mL, *p* = 0.002 and 4.86 AU/mL vs. 2.43 AU/mL, *p* = 0.04 respectively) (Fig. 6).

**Multivariable analyses**

Simultaneous relationships between patient and injury characteristics, complement activation, and outcome were explored in multivariable linear regression analyses (Tables S3 and S4 in Additional files 7 and 8). In the optimal model, admission TCC was associated with blunt mechanism of injury and decreasing admission BE, and to a lesser extent by increasing NISS (*R*² = 0.37). TCC-AUC₃–₆ was associated with admission TCC alone (*R*² = 0.64). VFD was associated with NISS and admission TCC (*R*² = 0.64), without any contribution from sex, age, injury mechanism and admission BE. For daily SOFA scores (Table S4 in Additional file 8), NISS and TCC-AUC₃–₆ were the only associated variables, and only on day 0 and 4 (*R*² = 0.60 and 0.58 respectively). All models were highly significant (*p* < 0.0001).

**Effects of major head injury**

Major head injury is a main determinant for outcome after trauma. In this study, patients with and without major head injury had 30-day mortality of 37% and 5% (*p* = 0.0005) respectively, and median (quartiles; range) VFD of 9 (0–28; 0–30) and 30 (29–30; 0–30) (*p* < 0.0001), respectively (Table S1 in Additional file 3). Variables associated with outcome for the two subgroups were therefore also analysed separately (Fig. 4 and Fig. S3 in
In multivariable models, VFD was associated with NISS alone in patients with major head injury ($R^2 = 0.52$) and by TCC-AUC$_{3–6}$, admission TCC, and NISS in those without ($R^2 = 0.59$). NISS contributed to SOFA score on Day 0 for both subgroups, together with same-day TCC in those with major head injury ($R^2 = 0.42$) and TCC-AUC$_{3–6}$ in those without ($R^2 = 0.41$). On Day 4, admission TCC was the sole variable associated with SOFA score in those with major head injury ($R^2 = 0.33$), while NISS and TCC-AUC$_{3–6}$ were associated in those without ($R^2 = 0.90$). There was insufficient data to establish covariates associated with SOFA score on Day 7 and 9 in either subgroup. All other models were highly significant ($p \leq 0.002$).

Discussion
This study shows that plasma concentrations of TCC are elevated following trauma, both in the initial hours and in the succeeding days. Moreover, patients with more severe injury characteristics, i.e. higher NISS and lower admission BE, have higher levels of TCC both at admission and accumulated 3–6 h after injury. Here, we explore individual TCC concentration curves and show that although TCC curves exhibit great variability in temporal shapes between individuals, there is a pattern; the highest values were generally seen within the first 6 h after trauma, before TCC levels subside to a slightly lower level but remain elevated throughout the ICU stay. We found that complement activation 3 to 6 h after admission is a better predictor of multiple organ dysfunction syndrome than admission TCC. Thus, this time period should be in focus in the design of future experimental studies and clinical trials using complement inhibitors.

The heterogeneity observed may be caused by diversity in patient background, trauma characteristics and treatment, and moreover by the complement system itself. It is dynamic and volatile after an enormous impact such as major trauma, and it is only to be expected that the end product of the complement cascade, TCC, varies in both concentrations and timing among individuals. Thus, although complement activation products have short half-lives in plasma, the downstream tissue consequences of complement activation may go on in the organs for days and weeks (Huber-Lang et al. 2018).

Multivariable analyses are useful to explore the relative importance of explanatory variables. We found blunt injury and deranged physiology to be the most important explanatory variables for admission TCC, with a smaller contribution from anatomical injury. Admission TCC in turn predicted TCC-AUC$_{3–6}$. We regard these data to fit well into our main hypothesis of the role of complement in the pathophysiology of remote organ dysfunction after severe trauma.

Complement activation was consistently associated with outcome. Both admission TCC and TCC-AUC$_{3–6}$ were important explanatory variables for the primary outcome VFD in patients without major head trauma, together explaining more than 73% of its variability. Moreover, TCC-AUC$_{3–6}$ together with NISS were the only predictors for our secondary outcome SOFA score.
at day 0 and 4, in the same subgroup. No association was found between complement activation and SOFA score at day 7 and 9. This may be caused by our relatively small sample of patients with longer ICU stays, or possibly indicate that remote organ dysfunction later in the ICU stay is influenced by other or additional factors. Alternatively, it may indicate that complement activation as measured by TCC in plasma is less important for remote organ dysfunction than complement activation locally in the tissues (Huber-Lang et al. 2018).

We found an association between complement activation and mortality in this study, however most deaths occurred early from unsurvivable head injuries. Independent of the cause of death, complement activation was significantly higher among the deceased and one can speculate if it is a contributing trigger, or a marker of the following event.

A substantial number of papers exist on complement activation after trauma with two or more serially collected samples per patient (Risberg et al. 1986; Fosse et al. 1987, 1998; Zilow et al. 1992; Donnelly et al. 1994; Meade et al. 1994; Roumen et al. 1995; Hecke et al. 1997; Amara et al. 2009; Burk et al. 2012; Li et al. 2019), the highest time resolution studied previously being samples every 4 h (Amara et al. 2009; Burk et al. 2012). Our study contributes with an even higher time resolution with samples every 2 h for the first 5 samples. Further, despite many studies having a repeated-measures design, to our knowledge, ours is the first to utilise this design by presenting and analysing complement concentration kinetics in

---

Fig. 4 Ventilator-free days. Terminal Complement Complex (TCC) vs. ventilator-free days (VFD) for patients without major head injury (open symbols) and with major head trauma (filled symbols). Admission TCC concentrations are shown in the two left panels and TCC-AUC₃–₆ in the two right panels, with linear fit and 95% confidence interval for the fitted line (shaded). $\rho$, Spearman’s rank correlation coefficient.
individual patients for up to 10 days after trauma. Studies utilising a repeated-measures design may have a better potential to answer clinically relevant questions, e.g. by generation of summary measures of time-varying data which can often be sufficiently analysed by simple statistical methods (Matthews et al. 1990). Our summary measure, TCC-AUC\textsubscript{-3,6}, outperformed admission TCC as a predictor both for VFD and for SOFA scores on day 0 and 4 in patients without major head injury. This is hardly surprising, as it encompasses TCC concentration over time during 3 critical hours early after trauma (Karasu et al. 2019; Groeneveld et al. 2011).

Our study has several limitations. First, an even higher sampling time resolution during an extended time period and a higher number of patients would probably discriminate patterns of TCC concentration curves better. Second, to include mechanism of injury as an explanatory variable in our multivariable analyses can be debated, as there were only 13% penetrating injuries in our population. Third, NISS as measure for injury severity scoring is not an accurate measure of total volume of tissue injury. Finally, the use of multivariable linear models when studying explanatory variables may be error prone, in particular when relationships between variables are suspected to be nonlinear, or when there are outliers. However, we did explore a non-linear approach with GAM, but this did only marginally influence the results.
Conclusions

The present data demonstrates that complement was activated early after trauma, generally reached its highest concentration within 6 h of injury, and remained elevated in ICU patients for several days after injury. The degree of complement activation in the first critical hours was associated with blunt injury, deranged physiology and high NISS. In patients without major head injury, TCC-AUC\textsubscript{3–6} outperformed admission TCC as a predictor for both VFD and SOFA score at day 0 and 4. Thus, the greatest surge of complement activation is found within the first 6 h after injury. This time period should be in focus when designing future experimental and clinical studies using complement inhibitors in the treatment of trauma.

Abbreviations

AIS: Abbreviated Injury Scale; AU: Arbitrary units; BE: Base excess; BIC: Bayesian information criterion; C3: Complement component 3; C3a: Complement component 3a; C5: Complement component 5; C5a: Complement component 5a; C5b-9: Complement component complex 5b-9; ELISA: Enzyme-linked immunosorbent assay; ICU: Intensive care unit; ISS: Injury Severity Score; K\textsubscript{2}EDTA: Dipotassium ethylenediaminetetraacetic acid; GAM: Generalised additive models; MAC: Membrane attack complex; MODS: Multiple organ dysfunction syndrome; NISS: New Injury Severity Score; OUH: Oslo University Hospital; SOFA score: Sequential Organ Failure Assessment score; STROBE: Strengthening the Reporting of Observational Studies in Epidemiology; TCC: Terminal complement complex; TCC-AUC\textsubscript{3–6}: Area under the individual TCC curve 3–6 hours after injury; VFD: Ventilator-free days.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s10020-021-00286-3.

Additional file 1. Methods.
Additional file 2: Figure S1. STROBE flow diagram.
Additional file 3: Table S1. Characteristics of trauma patients with and without major head injury.
Additional file 4. Figure S2. Time to death.
Additional file 5. Table S2. Correlation analyses.
Additional file 6. Figure S3. SOFA score versus TCC in patients with and without major head injury.
Additional file 7. Table S3. Regression analyses for ventilator-free days.
Additional file 8. Table S4. Regression analyses for SOFA scores.
Additional file 9. Figure S4. Assessment of SOFA scores.

Acknowledgements

We thank Julie Katrine Lindstad, Ivan Jonassen Rimså, Anne-Marie Sæbøe Træsæ, Linda Soliammi, Astrid Arnesen Hug, Erland Skaga and Tomas Drægni for invaluable help with design, data collection and data analysis, Morten Hestnes and Hans Johansson for their continuing efforts at the Oslo University Hospital trauma registry, and Ulf Kongsgaard for facilitation of the study throughout.

Authors’ contributions

TE initiated and designed the study and built the Oslo University Hospital trauma registry. SP and TEM contributed with specific expertise in complement biology, in design and execution of the study. JPB contributed with expertise in laboratory investigation methods. INR, WO and TE recruited and followed up patients, obtained and processed samples. CJ performed the
laboratory analyses. INR, JR and TE performed statistical analyses. INR drafted the manuscript. All authors critically evaluated and discussed the ongoing analyses, and critically revised the manuscript. All authors read and approved the final manuscript.

Funding
The study was financially supported by Oslo University Hospital, The University of Oslo, The Norwegian Air Ambulance Foundation, The University of Stavanger, South-Eastern Norway Regional Health Authority, The Research Council of Norway, The Odd Fellow Foundation and The Simon Foungar Man Fund.

Availability of data and materials
The data that support the findings of this study are available from Oslo University Hospital, but restrictions to their availability apply. The data belong to OUH and are subject to Norwegian legislation regarding hospital owned data.

Declarations

Ethics approval and consent to participate
All parts of the study were approved by the Regional committee for medical and health research ethics (2010/2014 REX Sar-013 D), in accordance with the Declaration of Helsinki. Patients were enrolled at admission. Written informed consent to participate was obtained as soon as practically possible. A temporary written consent from the closest relative was obtained when patients were unable to consent. All material was destroyed if patients or relatives did not consent. The Regional committee for medical and health research ethics approved the use of biological material from patients who died before consent could be obtained, and the use of written information with the possibility for withdrawal for patients who were transferred to other hospitals or discharged before consent could be obtained. All those patients were checked against the Norwegian national biological research reservation registry before final inclusion.

Consent for publication
Written informed consent for publication of non-identifiable data was obtained together with the consent to participate.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Research, The Norwegian Air Ambulance Foundation, Oslo, Norway. 2 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 3 Department of Anaesthesiology, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway. 4 Department of Immunology, Oslo University Hospital and University of Oslo, Oslo, Norway. 5 Faculty of Health Sciences, University of Stavanger, Stavanger, Norway. 6 Research Laboratory, Nordland Hospital, K.G. Jebsen TREC, Faculty of Health Sciences, The Arctic University of Norway, Bodø and Tromsø, Norway. 7 Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.

Received: 18 November 2020 Accepted: 3 March 2021 Published online: 08 April 2021

References
Amara U, Kalbitz M, Perl M, Flierl MA, Rittirsch D, Weiss M, Schneider M, Gebhard F, Huber-Lang M. Early expression changes of complement regulatory proteins (CRegs) and C5a receptor (CD88) on leukocytes after multiple injury in humans. Shock. 2009;33(6):568–75.
Balogh Z, Offner PJ, Moore EE, Biffi WL. NISS predicts postinjury multiple organ failure better than the ISS. J Trauma. 2000;48(4):624–7. discussion 627–628.
Bergslett G, Ludvigsen JK, Kirschfink M, Giclas PC, Nilsson B, Molnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56(3):232–9.
Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunoassays. Best Pract Res Clin Endocrinol Metab. 2013;27(5):67–61.
Burk AM, Martin M, Flierl MA, Rittirsch D, Helm M, Lampf L, Bruckner U, Stahl GL, Blom AM, Perl M, et al. Early complementopathy after multiple injuries in humans. Shock. 2012;37(4):345–54.
Cabrera CP, Mansson J, Shepherd JM, Torrance HD, Watson D, Longhi MP, Hoti M, Patel MB, O’Dwyer M, Nourshargh S, et al. Signatures of inflammation and impending multiple organ dysfunction in the hyperacute phase of trauma: a prospective cohort study. PLoS Med. 2017;14(7):e1002352.
Chakraborty S, Karasu E, Huber-Lang M. Complement after trauma: suturing innate and adaptive immunity. Front Immunol. 2019;10:2050.
Cole E, Gillepsie S, Villalpam Y, Bohi K. Organ dysfunction in trauma study c. multiple organ dysfunction after trauma. Br J Surg. 2020;107(4):402–12.
Donnelly TJ, Meade P, Jagels M, Cyer HG, Law MM, Hugli TE, Shoemaker WC, Abraham E. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med. 1994;22(5):768–76.
Fosse E, Molnes TE, Aassen AO, Trompy HJ, Stokke T. Complement activation following multiple injuries. Acta Chir Scand. 1987;153(3–4):325–30.
Fosse E, Pilgram-Larsen J, Svennevig JL, Nordby C, Skulberg A, Molnes TE, Abdelnoor M. Complement activation in injured patients occurs immediately and is dependent on the severity of the trauma. Injury. 1988;20(7):509–14.
Ganter MT, Bohi K, Cohen MJ, Shaffer LA, Walsh MC, Stahl GL, Pittet JF. Role of the alternative pathway in the early complement activation following major trauma. Shock. 2007;28(1):129–24.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.
Groeneveld KM, Leenen LP, Koenderman L, Kesecioglu J. Immunotherapy after trauma: timing is essential. Curr Opin Anaesthesiol. 2012;24(2):219–23.
Hajisengilis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD. Novel mechanisms and functions of complement. Nat Immunol. 2017;18(12):1288–98.
Harboe M, Thogersen EB, Molnes TE. Advances in assay of complement function and activation. Adv Drug Deliv Rev. 2011;63(12):976–87.
Hecke F, Schmidt U, Kola A, Bautsch W, Klos A, Kohl J. Circulating complement proteins in multiple trauma patients—correlation with injury severity, development of sepsis, and outcome. Crit Care Med. 1997;25(12):2015–24.
Huber-Lang M, Kortun A, Ignatius A. The role of complement in trauma and fracture healing. Semin Immunol. 2013;25(1):73–8.
Huber-Lang M, Lambris JD, Ward PA. Inmate immune responses to trauma. Nat Immunol. 2018;19(4):327–41.
Karasu E, Nilsson B, Kohl J, Lambris JD, Huber-Lang M. Targeting complement pathways in polytrauma- and sepsis-induced multiple-organ dysfunction. Front Immunol. 2019;10:543.
Li Y, Zhao Q, Liu B, Dixon A, Cancio L, Dubick M, Dalle Lucca J. Early complementopathy predicts the outcomes of patients with trauma. Trauma Surg Acute Care Open. 2019;4(1):e000217.
Lord JM, Midwinter MJ, Chen YF, Belli A, Brohi K, Kovacs EJ, Koenderman L, Kubes P, Lifshyt RJ. The systemic immune response to trauma: an overview of pathophysiology and treatment. Lancet. 2014;384(9952):1455–65.
Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300(6719):230–5.
Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–5.
Meade R, Shoemaker WC, Donnelly TJ, Abraham E, Jagels MA, Cyer HG, Hugli TE, Bishop MH, Wo CC. Temporal patterns of hemodynamics, oxygen transport, cytokine activity, and complement activity in the development of adult respiratory distress syndrome after severe injury. J Trauma. 1994;36(5):651–7.
Molnes TE, Lea T, Fraland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985;22(2):197–202.
Molnes TE, Garred P, Bergseth G. Effect of time, temperature and anticoagulant on in vitro complement activation. Consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol. 1988;73(3):484–8.
Morgan BP. The membrane attack complex as an inflammatory trigger. Immunobiology 2016;221(6):747–51.

Neath AA, Cavanaugh JE. The Bayesian information criterion: background, derivation, and applications. WIRE Comput Stat. 2012;4(2):199–203.

Nyutinck JK, Goris JA, Redd H, Schlag G, van Munster PJ. Posttraumatic complications and inflammatory mediators. Arch Surg. 1986;121(8):886–90.

Osler T, Baker SP Long W. A modification of the injury severity score that both improves accuracy and simplifies scoring. J Trauma. 1997;43(6):922–5. discussion 925–926.

Ottestad W, Rognes IN, Pischke SE, Mollnes TE, Andersson U, Eken T. Biphasic release of the alarmin high mobility group box 1 protein early after trauma predicts poor clinical outcome. Crit Care Med. 2019;47(8):e614–22.

Ouellet JF, Roberts DJ, Tiruta C, Kirkpatrick AW, Mercado M, Trottier V, Dixon E, Feliciano DV, Ball CG. Admission base deficit and lactate levels in Canadian patients with blunt trauma: are they useful markers of mortality? J Trauma Acute Care Surg. 2012;72(6):1532–5.

Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013;190(8):3839–47.

Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2011;7(6):331–41.

Risberg B, Medegard A, Heideman M, Gyzander E, Bundesen P, Oden M, Tegern-Nilsson AC. Early activation of humoral proteolytic systems in patients with multiple trauma. Crit Care Med. 1986;14(11):917–25.

Roumen RM, Redd H, Schlag G, Zilow G, Sandtner W, Koller W, Hendriks T, Goris RJ. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. Crit Care Med. 1995;23(4):474–80.

Saltelli A. Sensitivity analysis for importance assessment. Risk Anal. 2002;22(3):579–90.

Schoenfeld DA, Bernard GR. Network A. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30(8):1772–7.

Schoffel U, Bonnaire F, van Specht BJ, Kuner EH. Monitoring the response to injury. Injury. 1991;22(5):377–82.

Sharma DK, Sarda AK, Bhatla SA, Goyal A, Kulshreshtha VN. The effect of recent trauma on serum complement activation and serum C3 levels correlated with the injury severity score. Indian J Med Microbiol. 2004;22(3):147–52.

Vincent JL, de Mendonca A, Cantaine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1995;23(11):1793–800.

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.

Wood SN. Generalized additive models, 2nd edition. London: CRC Press Chapman & Hall; 2017. ISBN 9781498728331

Yehya N, Hathay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019;200(7):828–36.

Zilow G, Joka T, Obertacke U, Rother U, Kirschfink M. Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome. Crit Care Med. 1992;20(4):468–73.

Publisher's note
 Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.